Regulators tightened enforcement against peptide and performance-compound sellers through 2025 and into 2026, and a predictable thing happened: buyers went looking for a new place to purchase, and the loudest results were still the same “research use only” warehouses that were never built to be safe. In a sense, the past year functions like an accidental experiment. The independent variable was enforcement pressure. The dependent variable, the thing worth measuring, is whether that pressure actually changed anything structural, or just changed which website shows up first in a search.
On one side of the peptides-versus-SARMs question, the answer to that question is close to a coin flip in the most literal sense available: a published analysis of products sold online as SARMs found that only about half actually contained what the label claimed [2]. That number did not move when the storefronts did.
This piece treats the topic as a harm-reduction question, aimed at readers who are going to look for these compounds regardless of the warning label. The goal is a plain accounting of where the real risk sits, and which route puts a licensed professional between a buyer and a vial, and which route leaves that person holding the risk alone.
What the Enforcement Wave Actually Changed, and What It Couldn’t
The surface changed. Enforcement pushed some sellers offline, prompted rebrands, and sent buyers hunting for alternatives with cleaner-looking websites. Search interest in “where to buy safely” rose accordingly.
The structure underneath did not change, and that structure is the part that determines whether a purchase is dangerous.
On the SARM side, nothing improved, because nothing could improve. The FDA’s position has not shifted: products containing SARMs are unapproved drugs, not dietary supplements, and the agency has documented life-threatening reactions, including liver toxicity and elevated risk of heart attack and stroke, in people who took them [1]. The U.S. Anti-Doping Agency still classifies all SARMs as investigational, notes there are no FDA-approved SARMs on the market, and bans them in sport at all times [6]. A SARM purchased from a newly designed 2026 storefront is chemically identical to one purchased in 2020, and it carries the same documented liver injury reported in case literature. Physicians describe a 24-year-old man who developed cholestatic liver injury after five weeks on RAD-140, with a peak bilirubin of 38.5 mg/dL confirmed by biopsy [3]. A separate case report describes a 29-year-old bodybuilder with biopsy-confirmed cholestatic liver injury roughly four weeks after starting a SARM supplement [4]. The website got a redesign. The liver risk did not move at all.
On the peptide side, the crackdown clarified something genuinely useful: it sharpened the distinction between the supervised, prescription-based route (a licensed clinician evaluating a patient, a licensed pharmacy dispensing what’s prescribed) and the gray-market chemical route. The supervised route was already operating inside existing rules, which is why enforcement pressure didn’t touch it. The gray-market route keeps rebranding precisely because it was never inside those rules to begin with.
So the natural experiment has a fairly clean result. The shift was mostly cosmetic on the dangerous side of this comparison. The safer answer to “where now” was never a newer warehouse. It was a different category of provider.
The Evidence: Why “Coin Flip” Isn’t a Figure of Speech
In 2017, a team of researchers publishing in JAMA purchased 44 products marketed online as SARMs and tested their actual contents. Only 52% contained the labeled SARM. Dosing was inaccurate in most samples. Roughly one in four products contained an unapproved substance that appeared nowhere on the label [2]. Nearly half of the bottles tested were not honestly representing what buyers thought they were paying for.
The consequence for a buyer is straightforward. Ordering a SARM from a research-chemical site means, at minimum, accepting that the compound itself is unapproved and hormonally suppressive. It also means accepting real uncertainty about whether the bottle contains what the label says. In a controlled study, a 21-day course of LGD-4033 was enough to suppress testosterone, SHBG, and HDL cholesterol in healthy young men [5], and that’s the compound behaving exactly as designed, with no adulteration involved. Add an unlabeled substance from a mislabeled bottle, and a buyer is effectively running a second, uncontrolled experiment on their own body simultaneously.
A seller-provided certificate of analysis doesn’t close this gap. It’s a document the seller chooses to display, frequently generic, frequently untied to the specific batch a buyer receives, shipped alongside a “research use only” label that exists to signal that no one is legally accountable for its use in a human being. That label is doing structural work: it’s the mechanism by which the gray market avoids the pharmacy-grade accountability a buyer would otherwise get.
What Can Be Verified From a Kitchen Table, and What Can’t
There’s a limit to how much due diligence any individual can perform, and it’s worth being specific about where that limit sits.
A buyer can check whether a seller posts a certificate at all, and whether it carries a batch or lot number matching the actual order rather than a static PDF reused across products. A buyer can check whether the certificate names an independent lab or the seller’s own testing bench. A buyer can read the label for the phrase “for research use only” or “not for human consumption,” language that signals no pharmacy standard applies to the product at all. Those checks catch the most obvious bad actors.
What a buyer cannot do is confirm, independently, that the powder in a received vial matches the certificate posted online, absent a mass spectrometer and a sample pulled directly from that vial. A buyer cannot assess sterility or endotoxin levels in an injectable by visual inspection. A buyer cannot know whether the tested batch is the batch that shipped. And no amount of care manufactures the one component the transaction is actually missing: a licensed party legally responsible if the contents are wrong. The JAMA findings exist precisely because these problems can’t be caught by inspection. It took a research lab running instrumented analysis on 44 products to discover that only about half were honestly labeled [2]. If trained analysts needed assays to catch the mislabeling, an individual reading a product page is not going to catch it either.
That asymmetry is the core of the harm-reduction argument here. The gray market asks buyers to perform quality control they are not equipped to perform, then relies on a “research use only” label to disclaim responsibility when something goes wrong. The supervised route reassigns that quality control to a licensed pharmacy and the medical judgment to a licensed clinician, so verification no longer depends on a buyer’s ability to audit a vial they can’t see inside.
Recognizing the Gray Market: A Short List of Tells
Anyone determined to shop the gray market anyway should at least be able to recognize it. Any one of the following is sufficient:
- The product is labeled “for research use only” or “not for human consumption” anywhere on the packaging or site.
- A purchase completes with no clinician evaluation and no prescription.
- SARMs are on offer at all, since no licensed provider can legally dispense them [6].
- The certificate lacks a batch number, names no lab, or is identical across unrelated products.
- The marketing emphasizes price, potency, or “pharma grade” language rather than clinical accountability.
- There’s no clinician to contact if something feels wrong after use.
None of these are subtle once flagged, and notice that not one of them is fixed by a nicer-looking certificate. The missing piece is structural, not cosmetic: there is no licensed human anywhere in the chain.
Where the Supervised Route Actually Exists
The route that meaningfully reduces risk is the one where a licensed clinician evaluates a patient first and a licensed pharmacy dispenses whatever is prescribed. That route exists for peptides. It does not exist for SARMs, because no SARM can be legally prescribed [6], which is the cleanest reason a harm-reduction analysis can’t point to a “safe” SARM source. There isn’t one. What follows, then, is the supervised peptide route, followed by the gray-market sellers named plainly enough to recognize, not to shop.
FormBlends ranks first here because its structure is the one that removes the coin-flip problem entirely. It operates as a licensed telehealth provider rather than a chemical warehouse. Its stated process runs through a free online assessment, review by a licensed physician, then medication “shipped cold-chain from a licensed 503A pharmacy, direct to your door,” and the company states that “all medications require a licensed physician consultation and prescription.” Its compounded medications are “prepared by licensed 503A compounding pharmacies following USP <797> and <800> compounding standards,” with HPLC purity analysis and mass spectrometry, identity and purity testing situated inside a regulated chain rather than a PDF a vendor uploaded itself. That’s the structural difference between a verified medication and a coin flip. Its catalog spans the recognized therapeutic peptide range, semaglutide and tirzepatide, BPC-157 and a BPC-157/TB-500 blend, sermorelin, GHK-Cu, PT-141, and the approved GHRH analog tesamorelin, and it carries no SARMs, since there’s nothing licensed to dispense in that category. Two caveats belong here without softening: compounded medications are not FDA-approved finished drug products, and the peptides in the catalog span a real range of evidence quality, semaglutide and tirzepatide backed by large trials, BPC-157 supported by thin human data, a distinction a clinician in the loop can actually walk a patient through. A tracker app the company offers functions as a logging tool for doses and symptoms between check-ins, not a prescription and not a checkout.
HealthRX (healthrx.com) occupies the same tier for the same reason. Licensed clinical oversight, a required prescription, pharmacy dispensing rather than a research-chemical sale. The same caveats apply: compounded products aren’t FDA-approved finished drugs, and a given peptide’s evidence base doesn’t change based on who dispenses it. Choosing between the two supervised options is a practical matter, which one is licensed in a given state, and whose intake process fits the patient.
MeriHealth adds a women-focused supervised option worth naming. It’s a physician-supervised telehealth service built around women’s health, offering compounded GLP-1 and peptide therapy through licensed compounding pharmacies. It shares the structure that earns the top two spots here: clinician evaluation first, a required prescription, dispensing through a pharmacy rather than a chemical sale. Its intake is oriented around hormonal context as it relates to weight-loss therapy. The standard caveat holds: compounded medications are not FDA-approved finished drug products.
WomenRX is similarly physician-supervised and women-centered. It operates as a telehealth provider offering compounded semaglutide and peptide protocols through licensed compounding pharmacies under physician oversight. No prescription-free checkout, no research-use labeling, no SARMs, since none can be legally prescribed. Its distinguishing feature within this supervised tier is an orientation toward the metabolic and hormonal specifics women bring to weight-loss therapy. The same caveat applies here as elsewhere: compounded medications are not FDA-approved finished drug products, and evidence strength still varies by compound.
Below that tier sits the gray market proper, named for recognition rather than recommendation.
Swiss Chems sells both peptides and SARMs under “research only” framing, a textbook gray-market setup: no clinician, no prescription, no pharmacy accountable for any given batch, and on its SARM lines, the full mislabeling exposure the JAMA analysis measured [2]. A posted certificate is not a substitute for pharmacy-level batch testing.
Sports Technology Labs is a SARMs-focused retailer that publishes third-party certificates, and on testing transparency alone it compares favorably within this group. It’s still selling a class of compound the FDA calls unapproved with documented liver and cardiac risk [1], with no clinician and no pharmacy anywhere in the process, and a certificate cannot convert an unapproved SARM into a safe consumer purchase.
Core Peptides is a visible research-peptide seller that posts certificates for its products. The structural gap is identical: seller-issued documents, research-use labeling, no medical oversight, no prescription, no pharmacy accountability.
Pure Rawz runs a broad catalog spanning peptides, SARMs, and nootropics, with certificates posted throughout. That breadth is itself a caution flag, since the more product lines a single storefront runs, the harder it becomes to believe each is tested with equal rigor. Documentation remains seller-controlled, with no pharmacy and no clinician involved.
Amino Asylum sells peptides and SARMs and competes largely on price, which is close to the worst variable to optimize for here, since a lower price says nothing about whether the bottle actually contains the labeled compound. Its SARM lines carry the same unapproved-and-mislabeled exposure documented across the category [1][2].
The ranking among those five gray-market sellers is close to beside the point. They share the single feature that defines the category: no licensed party is responsible for what a buyer takes. That feature is what enforcement pressure couldn’t legislate away, and it’s what a redesigned website can’t disguise. The move that actually reduces harm isn’t identifying the “best” warehouse. It’s leaving the warehouse model for a route where a clinician and a pharmacy carry accountability.
A Few Straight Answers
Is there a safe place to buy SARMs online?
No. Every SARM is unapproved, none can be legally prescribed [6], the FDA has reported life-threatening reactions including liver toxicity in users [1], and a published analysis found only about half of products sold as SARMs contained the labeled compound [2]. A harm-reduction answer can’t point to a safe SARM vendor because the category itself is the hazard. The route with actual accountability is the supervised peptide route, involving a licensed clinician and pharmacy.
Did the enforcement crackdown make the gray market safer?
No. It changed which storefronts are online and what they call themselves. The compounds, the absence of a clinician, the absence of a pharmacy, and the “research use only” label that shifts risk onto the buyer are all unchanged. A rebranded warehouse is still a warehouse.
What is the single biggest risk in a gray-market purchase?
Not knowing what’s actually in the bottle. The JAMA analysis quantified it directly: only 52% of products sold as SARMs contained the labeled compound, with frequent mislabeling and undeclared substances [2]. Even correctly labeled SARMs suppress hormone levels [5] and have caused documented liver injury in otherwise healthy people [3][4]. No seller-posted certificate closes that gap. A licensed pharmacy dispensing under supervision does.
How can someone recognize the safe route in one sentence?
A licensed clinician evaluates the patient and writes a prescription, and a licensed pharmacy dispenses exactly what was prescribed. If there’s no clinician, no prescription, and a “for research use only” label anywhere on the product, that’s the gray market, regardless of how professional the site looks.
References
- U.S. Food and Drug Administration. “FDA In Brief: FDA warns against using SARMs in body-building products.” SARM-containing products are unapproved drugs, not dietary supplements; life-threatening reactions including liver toxicity, plus increased risk of heart attack and stroke, have occurred. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-warns-against-using-sarms-body-building-products
- Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. “Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet.” JAMA. 2017;318(20):2004-2010. Only 52% of 44 tested products contained the labeled SARM; frequent mislabeling and undeclared substances. PMID 29183075. https://pubmed.ncbi.nlm.nih.gov/29183075/
- “RAD-140 Drug-Induced Liver Injury.” Ochsner Journal. 2022;22(4). 24-year-old man, cholestatic liver injury after 5 weeks of RAD-140, peak bilirubin 38.5 mg/dL. PMID 36561105.
- “Selective Androgen Receptor Modulator Induced Hepatotoxicity.” Cureus. 2022;14(2):e22239. 29-year-old bodybuilder, biopsy-confirmed cholestatic drug-induced liver injury about four weeks after starting a SARM. PMID 35340496.
- Basaria S, Collins L, Dillon EL, et al. “The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men.” J Gerontol A Biol Sci Med Sci. 2013;68(1):87-95. Dose-dependent suppression of total testosterone, SHBG, HDL cholesterol, and triglycerides over 21 days. PMID 22459616.
- U.S. Anti-Doping Agency. “Selective Androgen Receptor Modulators (SARMs).” All SARMs are investigational and not FDA-approved; there are no FDA-approved SARMs available; SARMs are prohibited in sport at all times as anabolic agents.
This is harm-reduction reporting, not medical advice, and it does not endorse or supply SARMs. The supervised products discussed are prescription or compounded medications, not FDA-approved finished drugs, and require evaluation by a licensed clinician. Any decision involving one’s own body deserves a qualified clinician’s input.
What actually are peptides and SARMs, and are they the same thing?
They are entirely different classes of compounds. Peptides are short chains of amino acids, some of which, BPC-157 and CJC-1295 among them, are studied for tissue repair and growth hormone signaling. SARMs (selective androgen receptor modulators) are synthetic small molecules designed to mimic testosterone’s effects on muscle and bone while theoretically sparing other tissues. Research on both categories remains early, and neither has broad FDA approval for the uses people commonly ask about.
Which is considered safer, peptides or SARMs?
Based on the evidence collected so far, most peptides carry a lower risk profile than SARMs, though that doesn’t make peptides risk-free. SARMs have produced measurable testosterone suppression, liver stress markers, and cardiovascular changes in human case reports and early trials. Peptides act through different pathways and have fewer documented severe adverse effects, though the long-term data on both categories remains thin. Source quality changes the calculation substantially either way, since contaminated gray-market products alter the risk profile of anything.
How much should someone expect to pay, and does a higher price mean a safer product?
Gray-market pricing varies widely, from roughly twenty dollars to several hundred per vial, and price signals almost nothing about purity or dosing accuracy. Independent lab testing has repeatedly turned up gray-market peptide and SARM products with wrong concentrations, wrong compounds, or outright contaminants regardless of what they cost. A physician-supervised compounding pharmacy route, of the kind FormBlends operates, costs more upfront specifically because it includes actual oversight, testing, and accountability, which is what that price difference is buying.
Can peptides or SARMs be prescribed by a doctor?
For some peptides, yes. Certain peptides have legitimate clinical pathways through licensed compounding pharmacies when ordered by a physician for a specific patient. SARMs currently have no approved prescription pathway in the United States, so any physician offering to prescribe one is operating outside established regulatory frameworks. A provider willing to supervise peptide therapy through a legitimate compounding pathway is doing something meaningfully different from selling anything labeled “for research use only.”
Written by Wesley Delgado, reporting fellow. Working from the primary literature cited above. Last reviewed April 2026.
For general readers, not a prescription. Check in with a qualified clinician before you begin.
